MedTrace Logo

Studying Biomarkers in Nipple Fluid, Urine, and Blood Samples From Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer and in Women at Risk of Developing Breast Cancer

NCT00897208 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 316

Last updated 2018-10-05

No results posted yet for this study

Summary

RATIONALE: Studying samples of nipple fluid, urine, and blood in the laboratory from patients with cancer and from patients at risk of developing cancer may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors learn more about breast cancer and identify patients at risk of developing breast cancer.

PURPOSE: This laboratory study is looking at biomarkers in nipple fluid, urine, and blood samples from women with newly diagnosed ductal carcinoma in situ or stage I or stage II breast cancer and in women at risk of developing breast cancer.

Conditions

Interventions

OTHER

high performance liquid chromatography

OTHER

laboratory biomarker analysis

OTHER

mass spectrometry

OTHER

medical chart review

PROCEDURE

evaluation of cancer risk factors

Sponsors & Collaborators

Principal Investigators

  • Sandhya Pruthi, MD · Mayo Clinic

Eligibility

Min Age
19 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-05-20
Primary Completion
2010-06-17
Completion
2015-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00897208 on ClinicalTrials.gov